ChemoCentryx Inc (NASDAQ:CCXI) Major Shareholder Sells $4,027,827.02 in Stock

ChemoCentryx Inc (NASDAQ:CCXI) major shareholder (International) Ltd Vifor sold 72,469 shares of the stock in a transaction on Wednesday, July 22nd. The stock was sold at an average price of $55.58, for a total value of $4,027,827.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

(International) Ltd Vifor also recently made the following trade(s):

  • On Friday, July 24th, (International) Ltd Vifor sold 133,074 shares of ChemoCentryx stock. The stock was sold at an average price of $54.62, for a total value of $7,268,501.88.
  • On Monday, July 20th, (International) Ltd Vifor sold 54,598 shares of ChemoCentryx stock. The stock was sold at an average price of $56.03, for a total value of $3,059,125.94.
  • On Friday, July 17th, (International) Ltd Vifor sold 47,890 shares of ChemoCentryx stock. The stock was sold at an average price of $55.86, for a total value of $2,675,135.40.
  • On Wednesday, July 15th, (International) Ltd Vifor sold 86,298 shares of ChemoCentryx stock. The stock was sold at an average price of $59.22, for a total value of $5,110,567.56.
  • On Monday, July 13th, (International) Ltd Vifor sold 100,000 shares of ChemoCentryx stock. The stock was sold at an average price of $58.15, for a total value of $5,815,000.00.
  • On Friday, July 10th, (International) Ltd Vifor sold 45,844 shares of ChemoCentryx stock. The stock was sold at an average price of $59.92, for a total value of $2,746,972.48.
  • On Wednesday, July 8th, (International) Ltd Vifor sold 100,000 shares of ChemoCentryx stock. The stock was sold at an average price of $59.95, for a total value of $5,995,000.00.
  • On Monday, July 6th, (International) Ltd Vifor sold 86,690 shares of ChemoCentryx stock. The stock was sold at an average price of $58.44, for a total value of $5,066,163.60.
  • On Thursday, July 2nd, (International) Ltd Vifor sold 87,781 shares of ChemoCentryx stock. The shares were sold at an average price of $57.47, for a total value of $5,044,774.07.

CCXI opened at $52.20 on Monday. The business’s 50-day moving average is $58.58 and its two-hundred day moving average is $49.73. ChemoCentryx Inc has a 1 year low of $6.16 and a 1 year high of $65.43. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.22 and a quick ratio of 3.22. The firm has a market capitalization of $3.23 billion, a PE ratio of -47.89 and a beta of 2.04.

ChemoCentryx (NASDAQ:CCXI) last issued its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.05). The business had revenue of $6.01 million during the quarter, compared to analyst estimates of $8.90 million. ChemoCentryx had a negative return on equity of 100.55% and a negative net margin of 192.93%. As a group, sell-side analysts expect that ChemoCentryx Inc will post -1.39 EPS for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of CCXI. Victory Capital Management Inc. boosted its holdings in ChemoCentryx by 45.9% in the fourth quarter. Victory Capital Management Inc. now owns 9,914 shares of the biopharmaceutical company’s stock worth $392,000 after acquiring an additional 3,120 shares in the last quarter. Great West Life Assurance Co. Can acquired a new stake in ChemoCentryx in the fourth quarter worth about $111,000. Raymond James Financial Services Advisors Inc. acquired a new stake in ChemoCentryx in the fourth quarter worth about $275,000. Raymond James & Associates boosted its holdings in ChemoCentryx by 56.9% in the fourth quarter. Raymond James & Associates now owns 31,014 shares of the biopharmaceutical company’s stock worth $1,227,000 after acquiring an additional 11,247 shares in the last quarter. Finally, Credit Suisse AG boosted its holdings in ChemoCentryx by 53.2% in the fourth quarter. Credit Suisse AG now owns 27,043 shares of the biopharmaceutical company’s stock worth $1,069,000 after acquiring an additional 9,393 shares in the last quarter. 70.37% of the stock is owned by institutional investors and hedge funds.

Several equities analysts have recently commented on the company. Piper Sandler raised their price target on ChemoCentryx from $54.00 to $70.00 and gave the company an “overweight” rating in a research note on Monday, May 18th. Zacks Investment Research lowered ChemoCentryx from a “buy” rating to a “hold” rating in a research note on Tuesday, May 12th. BidaskClub lowered ChemoCentryx from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Raymond James raised their price target on ChemoCentryx from $38.00 to $102.00 and gave the company a “strong-buy” rating in a research note on Tuesday, May 12th. Finally, JPMorgan Chase & Co. raised their price target on ChemoCentryx from $61.00 to $64.00 and gave the company an “overweight” rating in a research note on Thursday, May 14th. Two analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $69.00.

ChemoCentryx Company Profile

ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy.

Featured Article: New Google Finance Tool and Screening Stocks

Insider Buying and Selling by Quarter for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.